AEON Biopharma
AEON
17 hedge funds and large institutions have $12M invested in AEON Biopharma in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.
0.82% more ownership
Funds ownership: 0.1% → 0.92% (+0.82%)
19% less funds holding
Funds holding: 21 → 17 (-4)
41% less capital invested
Capital invested by funds: $20.5M → $12M (-$8.47M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$110K |
| 2 |
Walleye Trading
New York
|
+$100K |
| 3 |
CAC
Cowen and Company
New York
|
+$97.6K |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$56.9K |
| 5 |
Walleye Capital
New York
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$1.59M |
| 2 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
-$1.07M |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$1.01M |
| 4 |
GCWM
Graham Capital Wealth Management
Washington D.c.,
District of Columbia
|
-$997K |
| 5 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$811K |
AEON Hedge Fund Activity: Q2 2023 in Review
17 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2023, worth a combined $12M — down 41% from $20.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AEON and 3 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Clear Street, adding an estimated $110K. The largest seller was Glazer Capital LLC, cutting an estimated $1.59M.
- 17 institutional investors held AEON Biopharma (AEON) as of Q2 2023, down from 21 in Q1 2023.
- Funds reported $12M of AEON Biopharma stock for Q2 2023, down 41% quarter-over-quarter.
- 3 funds opened new AEON Biopharma positions in Q2 2023 and 7 closed out, a net change of -4 holders.
- The largest AEON Biopharma buyer in Q2 2023 was Clear Street, an estimated $110K added.
- The largest AEON Biopharma seller in Q2 2023 was Glazer Capital LLC, an estimated $1.59M sold.
Based on aggregated 13F filings for Q2 2023.